Mereo BioPharma
MREO · Nasdaq · United Kingdom
Share price · MREO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MREO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 23 Sep 2026+7.6%
Nothing announced by MREO that day or the session before.
- 11 Sep 2026+14.5%
Nothing announced by MREO that day or the session before.
- 11 Aug 2026+12.2%
- 31 Jul 2026+8.8%
Nothing announced by MREO that day or the session before.
- 2 Jun 2026+10.1%
- 26 May 2026+20.1%
Nothing announced by MREO that day or the session before.
- 20 May 2026+18.9%
Nothing announced by MREO that day or the session before.
- 6 May 2026-15.1%
Nothing announced by MREO that day or the session before.
- 4 May 2026+10.4%
Nothing announced by MREO that day or the session before.
- 9 Jan 2026+28.6%
Nothing announced by MREO that day or the session before.
Share of unusual movement by asset
For each asset, the share of MREO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
alvelestatevents and moves
| 1 | shown from 8 days |
setrusumabevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 39% |
| Other company news (earnings, financing, releases naming no asset) | — | 14% |
| Sessions with no dated event | — | 47% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | SclerostinMonoclonal antibody | Osteogenesis Imperfecta | |
| Phase 2 | Neutrophil elastaseSmall molecule | Chronic Obstructive Pulmonary DiseaseAlpha-1 Antitrypsin Deficiency |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
January 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (12)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.8M | $2.1M | $26M | $5.9M-$4.0M operating cash flow | report ↗ |
View 11 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $1.8M | $30M | $7.0M-$6.0M operating cash flow | report ↗ |
| 2026-Q1 | — | $4.8M | $36M | $6.7M | report ↗ |
| 2025-Q3 | $0 | $4.3M | $49M | $7.0M-$7.3M operating cash flow | report ↗ |
| 2025-Q2 | $0.5M | $5.4M | $56M | $15M-$7.7M operating cash flow | report ↗ |
| 2025-Q1 | — | $3.9M | $62M | $13M-$8.3M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $3.2M | $81M | $15M-$7.5M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $5.0M | $87M | $12M-$7.9M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $4.0M | $49M | $8.9M-$8.0M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $3.6M | — | $6.5M$2.7M operating cash flow | report ↗ |
| 2023-Q2 | $9.0M | $3.7M | — | $1.8M-$7.8M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $5.3M | — | $12M-$9.3M operating cash flow | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.5M | $18M | $41M | $10M-$31M operating cash flow | report ↗ |
Mereo BioPharma reported FY2025 revenue of $0.5M versus $0M in the prior year, with R&D spend of $17.77M, down 15.1% YoY, and cash and equivalents of $40.99M as of December 31, 2025. The company recorded a net loss of $41.88M for the year.
Management guided that existing cash is expected to fund operations into mid-2027. The Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta missed their primary endpoints but achieved high statistical significance on the key secondary endpoint of bone mineral density, with further analyses ongoing. Alvelestat Phase 3 site feasibility work is complete ahead of a planned ~220-patient pivotal trial, and partner Ashibio plans to initiate a Phase 2 study of vantictumab in osteopetrosis in the second half of 2026.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-02-26 | WYZGA MICHAEL S · director | Award / grant (derivative) | 66,000 | — | — | Form 4 |
| 2026-02-26 | Jenkins Annalisa · director | Award / grant (derivative) | 66,000 | — | — | Form 4 |
| 2026-02-26 | PAKIANATHAN DEEPIKA · director | Award / grant (derivative) | 66,000 | — | — | Form 4 |
| 2026-02-26 | Bender Jeremy · director | Award / grant (derivative) | 66,000 | — | — | Form 4 |
| 2026-02-26 | Ekblom Anders · director | Award / grant (derivative) | 66,000 | — | — | Form 4 |
| 2026-02-26 | Shames Daniel · director | Award / grant (derivative) | 66,000 | — | — | Form 4 |
| 2026-02-26 | Yoskowitz Marc J · director | Award / grant (derivative) | 66,000 | — | — | Form 4 |
| 2026-02-26 | Jacquet Pierre · director | Award / grant (derivative) | 66,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 63 reporting institutions held 75.4M shares ($24.8M, 47.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Rubric Capital Management LP | 15,307,347 | $5.1M |
| 2 | EcoR1 Capital, LLC | 13,368,855 | $4.4M |
| 3 | 683 Capital Management, LLC | 12,000,000 | $4.0M |
| 4 | BANK OF AMERICA CORP /DE/ | 8,195,287 | $2.7M |
| 5 | Defilade Capital Management, L.P. | 7,558,756 | $2.5M |
| 6 | Newtyn Management, LLC | 7,079,056 | $2.3M |
| 7 | MILLENNIUM MANAGEMENT LLC | 3,559,103 | $1.2M |
| 8 | Tejara Capital Ltd | 2,037,520 | $672K |
| 9 | UBS Group AG | 1,490,128 | $492K |
| 10 | Wealthspire Advisors, LLC | 796,036 | $263K |
| 11 | MARSHALL WACE, LLP | 686,987 | $227K |
| 12 | GROUP ONE TRADING LLC | 335,827 | $111K |
| 13 | Rangeley Capital, LLC | 329,200 | $109K |
| 14 | BlackRock, Inc. | 302,991 | $100K |
| 15 | Knott David M Jr | 300,337 | $99K |